Microbot Medical Expand IP protection in Japan
22 Junho 2023 - 9:36AM
Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY®
Robotic Surgical System, the first single-use endovascular robotic
surgical system, today announced the expansion of its global IP
portfolio by receiving a Grant of Protection from the Japan Patent
Office for a Design Patent covering the innovative industrial
design of the robotic drive of the LIBERTY Robotic Surgical System.
Microbot’s IP portfolio for LIBERTY and its
related technologies includes 19 patents issued/allowed and 41
applications pending.
This Design Patent complements previously
received protection in Japan covering the unique design of the
LIBERTY Robotic System remote controller. Similar Design Patents
were granted in the U.S., Europe, and Israel.
Noa Ofer, Senior Director of IP, said, "We are
thrilled to receive additional validation and protection for our
LIBERTY Robotic Surgical System. As we continue our regulatory
efforts, receiving patent allowances and grants in major global
territories is not only enhancing our intellectual property
portfolio but also reinforcing our commitment to bring cutting-edge
robotic technologies to healthcare professionals and patients
worldwide."
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The LIBERTY® Robotic Surgical System aims to
improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome,
and expensive capital equipment, while reducing radiation exposure
and physician strain. The Company believes the LIBERTY® Robotic
Surgical System’s remote operation has the potential to be the
first system to democratize endovascular interventional
procedures.Further information about Microbot Medical is available
at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY, the outcome of its studies
to evaluate LIBERTY, whether the Company’s core business focus
program and cost reduction plan are sufficient to enable the
Company to continue to focus on its LIBERTY technology while it
seeks additional working capital, any failure or inability to
recruit physicians and clinicians to serve as primary investigators
to conduct regulatory studies which could adversely affect or delay
such studies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals,
uncertainty resulting from the COVID-19 pandemic, need and ability
to obtain future capital, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can
be found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024